London midday: Stocks slightly higher; GSK jumps on guidance …

3 days ago · London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war, with GSK surging after it lifted its long-term …

CouponFollow Extension

4%
OFF

FTSE 100 Movers: GSK Surges On Guidance; DCC In The Red

2 weeks from now

3 days ago · London’s FTSE 100 was up 0.4% at 8,604.03 in afternoon trade on Wednesday. Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual …

sharecast.com

4%
OFF

LONDON MARKET MIDDAY: FTSE 100 Edges Up, Gold... | Morningstar

2 weeks from now

3 days ago · Earnings from GSK were better received in London, with the stock rising 6.4%. It raised its long-term sales guidance and announced a GBP2 billion share buyback, reflecting …

morningstar.co.uk

6%
OFF

GSK Stock Higher On Revised Long-term Guidance (GSK:NYSE)

2 weeks from now

3 days ago · GSK shares added ~6% in London trading on Wednesday after the British drugmaker lifted its 2031 outlook and announced a new share buyback program alongside …

seekingalpha.com

$2
OFF

GSK Stock Jumps On Long-Term Outlook Boost, $2.5B Share …

2 weeks from now

3 days ago · GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of …

investopedia.com

$2869.66
OFF

FTSE 100 Slightly Higher At Midday, Trade War Worries Linger

2 weeks from now

3 days ago · Gold rose to $2,869.66 an ounce midday Wednesday, from $2,840.78 at the time of the London equities close on Tuesday. Bullion hit a record high of $2,877.02 an ounce on …

sharesmagazine.co.uk

5%
OFF

GSK Shares Leap 5% As Results Top Forecasts And Guidance Is …

2 weeks from now

3 days ago · Image source: Getty images. GSK shares ended 2024 on a sour note after what proved to be a rollercoaster year.. The pharma giant dropped 7% over the 12 months, as …

yahoo.com

$2
OFF

London Open: Stocks Nudge Lower As Investors Keep An Eye On …

2 weeks from now

Jan 14, 2025 · London midday: Stocks slightly higher; GSK jumps on guidance upgrade GSK ups five-year sales outlook, unveils $2bn buyback London open: FTSE nudges up; GSK surges on …

sharecast.com

FAQs about London midday: Stocks slightly higher; GSK jumps on guidance … Coupon?

Why is GSK's share price rising?

On top of this, developing medicines is highly complex and therefore unpredictable. Setbacks and the testing or registration phases can, through a blend of sales issues and extra costs, leave earnings forecasts in tatters. Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains. ...

How did GSK's growth affect specialty medicine sales?

GSK said that “ continued growth across disease areas ” pushed Specialty Medicine sales 19% higher at stable currencies, to £11.8bn. Oncology was the standout here, with revenues almost doubling year on year on the same basis (up 98%). Strength here more than offset a 4% sales decline at the firm’s Vaccines division. ...

Why did GSK hike its 2031 sales target?

GSK also hiked its 2031 sales target, which it said reflected “ late-stage pipeline progres s”. Turnover is now tipped at £40bn, a £2bn upgrade from prior targets. Today, the company has 71 Specialty Medicines and Vaccines in clinical development. Of these, 19 are at the Phase III testing or registration phases. ...

How will GSK perform in 2031?

The Footsie firm expects turnover to rise between 3% and 5% at constant currencies, and core operating profit to advance between 6% and 8%. GSK also hiked its 2031 sales target, which it said reflected “ late-stage pipeline progres s”. Turnover is now tipped at £40bn, a £2bn upgrade from prior targets. ...

What happened to GSK's operating profit?

At group level, GSK’s operating profit dropped 33% and 40% at actual and constant currencies, respectively, to £4bn. It reflected a £1.8bn charge as the business settled US claims that its Zantac heartburn drug caused cancer. Core operating profit, which strips out these litigatory headwinds, rose 11% from 2023 levels. ...

Why are GSK's earnings forecasts in tatters?

As GSK witnessed last year with Arexy, changes to the regulatory environment can cause havoc among certain product lines. On top of this, developing medicines is highly complex and therefore unpredictable. Setbacks and the testing or registration phases can, through a blend of sales issues and extra costs, leave earnings forecasts in tatters. ...